Chemotherapy and Unrelated Donor SCT for Blood and Immune System Cancers

Background: Major problems with stem cell transplantation (SCT) for cancer treatment are a lack of suitable donors for patients without an HLA tissue-matched sibling and graft-versus-host disease (GVHD), a serious side effects of immune-suppressing chemotherapy that is given to bring the cancer under control before SCT. In GVHD, the patient's immune system attacks the transplanted donor cells. This study will try to improve the results of SCT from unrelated HLA-matched donors using targeted immune-depleting chemotherapy to bring the cancer under control before transplantation and to lower the chance of graft rejection, followed by reduced-intensity transplant chemotherapy to make the procedure less toxic. Objectives: To evaluate the safety and effectiveness of targeted immune-depleting chemotherapy followed by reduced-intensity transplant chemotherapy in patients with advanced cancers of the blood and immune system. To evaluate the safety and effectiveness of two different drug combinations to prevent GVHD. Both regimens have been successful in preventing GVHD, but they work by different mechanisms and affect the rebuilding of the immune system after the transplant. Eligibility: People 18 to 74 years of age with advanced or high-risk cancers of the blood and immune system who do not have a suitable HLA-matched sibling. Design: All patients receive chemotherapy before transplant to treat the cancer and suppress immune function. All patients receive a conditioning regimen of cyclophosphamide for 4 days and fludarabine for 4 days before SCT to prepare for the transplant. Patients are randomly assigned to one of two combination drug treatments to prevent GHVD as follows: Group 1: Tacrolimus starting 3 days before SCT and continuing for 6 months, plus methotrexate on days 1, 3, 6, and 11 post-SCT, plus sirolimus starting 3 days before the SCT and continuing through day 14 following SCT. Group 2: Alemtuzumab for 4 days starting 8 days before SCT, plus cyclosporine starting 1 day before SCT and continuing for 6 months. Patients receive the donor's stem cells and immune cells 2 days after the conditioning regimen. Patients are followed at the clinic regularly for the first 6 months after SCT, and then less often for at least 5 years. Some visits may include bone marrow aspirates and biopsies, blood draws, and other tests to monitor disease status. A skin biopsy, oral mucosa biopsy, and saliva collection are done to study chronic GVHD.]]>
Ages Eligible for Study: 18 Years to 74 Years Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria ELIGIBILITY CRITERIA RECIPIENT ON STANDARD CARE THERAPY: The patient is 18-74 years of age. The patient has a potentially suitable 8/8 donor if they are between the ages of 69-74 years of age or a potentially suitable 8/8 or 7/8 unrelated donor(s) in the National Marrow Registry or Other Available Registry if they are between the ages of 18-74. The patient currently does not meet the protocol s eligibility/enrollment criteria for any reason. There is a high likelihood that the patient, in the opinion of the principal investigator (PI) or lead associate investigator (LAI), will meet the protocols eligibility/enrollment criteria to proceed to transplant after standard therapy is completed. The patient or legal guardian is able to give informed consent. EXCLUSION CRITERIA RECIPIENT ON STANDARD CARE THERAPY: Human immunodeficiency virus (HIV) infection. There is theoretical concern that the degree of immune suppression associated with the treatment may result in progression of HIV infection. Pregnant or lactating. Patients of childbearing potential must use an effective method of contraception. The effects of the chemotherapy, the subsequent transplant and the medications used after the transplant are highly likely to be harmful to a fetus. The effects upon breast milk are also unknown and may be harmful to the infant.]]>
21-Aug-07 None (earliest Version on record) 18-Sep-07 Study Status 13-Oct-07 Study Description and Study Status 17-Oct-07 Study Status, Eligibility and Study Description 19-Oct-07 Arms and Interventions and Study Status 25-Oct-07 Arms and Interventions and Study Status 2-Nov-07 Arms and Interventions and Study Status 16-Nov-07 Study Status 25-Dec-07 Study Status 1-Feb-08 Study Status, Eligibility and Study Design 16-May-08 Study Status and Eligibility 23-May-08 Arms and Interventions and Study Status 7-Jun-08 Arms and Interventions and Study Status 23-Jul-08 Study Design and Study Status 29-Jul-08 Study Status 23-Aug-08 Arms and Interventions and Study Status 18-Oct-08 Sponsor/Collaborators, Contacts/Locations and Study Status 22-Oct-08 Study Status 13-Nov-08 Conditions and Study Status 11-Dec-08 Sponsor/Collaborators, Contacts/Locations and Study Status 19-Dec-08 Study Description and Study Status 20-Dec-08 Eligibility, Study Description and Study Status 31-Jan-09 Study Status 6-Feb-09 Arms and Interventions and Study Status 15-Apr-09 Study Status and Study Identification 21-Apr-09 Study Status, Eligibility, Outcome Measures, Study Design and Study Description 7-Jul-09 Study Status 12-Sep-09 Eligibility, Arms and Interventions, Study Description and Study Status 26-Nov-09 Eligibility and Study Status 20-Feb-10 Conditions and Study Status 9-Apr-10 Arms and Interventions, Eligibility, Conditions, Study Description and Study Status 17-Apr-10 Conditions and Study Status 3-May-10 Eligibility and Study Status 29-Jun-10 Study Identification and Study Status 30-Jun-10 Contacts/Locations, Study Status, Outcome Measures, Study Identification, Conditions, Study Description, References, Eligibility, Study Design, Oversight and Sponsor/Collaborators 7-Jul-10 Study Status 17-Sep-10 References and Study Status 21-Oct-10 Study Status 21-Dec-10 Study Design, Study Description and Study Status 11-Jan-11 Outcome Measures and Study Status 25-Jan-11 Eligibility and Study Status 12-Mar-11 Study Status 28-Apr-11 Study Description and Study Status 30-Apr-11 Study Description and Study Status 7-Jul-11 Study Status 30-Aug-11 Contacts/Locations and Study Status 23-Sep-11 Eligibility and Study Status 16-Nov-11 Study Description and Study Status 29-Dec-11 Contacts/Locations and Study Status 14-Mar-12 Contacts/Locations and Study Status 2-Jun-12 Study Status 27-Jun-12 Study Status 28-Jun-12 Study Status 12-Jul-12 Eligibility and Study Status 8-Dec-12 Sponsor/Collaborators and Study Status 6-Apr-13 Contacts/Locations, Study Status and Study Identification 27-Apr-13 Contacts/Locations and Study Status 1-May-13 Contacts/Locations and Study Status 21-May-13 Outcome Measures, Eligibility, Study Description and Study Status 20-Aug-13 Study Status 6-Sep-13 Study Status 27-Nov-13 Study Description, Eligibility and Study Status 6-Dec-13 Contacts/Locations and Study Status 14-Jan-14 Contacts/Locations and Study Status 14-Feb-14 Study Description, Eligibility and Study Status 19-Feb-14 Study Description, Eligibility and Study Status 14-Mar-14 Study Status 5-Apr-14 Outcome Measures and Study Status 15-Apr-14 Study Status 3-May-14 Contacts/Locations and Study Status 5-Jun-14 Study Description and Study Status 20-Mar-15 References and Study Status 1-Apr-15 Arms and Interventions and Study Status 12-Sep-15 Study Status 28-Oct-15 Recruitment Status, Contacts/Locations, Study Status, Study Design and References 7-Nov-15 Study Status 17-Feb-16 Study Status 4-Mar-16 Contacts/Locations and Study Status 27-Apr-16 Study Status 11-May-16 Study Status 23-Aug-17 Study Status, Outcome Measures, Arms and Interventions, Oversight, Sponsor/Collaborators, Study Description, Results, IPDSharing, References, Contacts/Locations and Eligibility 7-May-18 Study Status and More Information 11-Feb-19 Recruitment Status, Study Status, Outcome Measures, Documents, More Information and Sponsor/Collaborators]]>